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of SLE and RA, and mental health parameters.  Results: Four-
teen RA and 27 SLE patients had sSS. The autoantibody levels 
to all epitopes of m3AChR were significantly higher in pSS 
and SLE patients than in the controls. The fusion protein 
forms discriminated RA from pSS and SLE; furthermore, the 
YNIP fusion protein also distinguished pSS from SLE. The 
prevalence and the mean levels of all autoantibodies did not 
differ statistically between sicca and non-sicca SLE or RA pa-
tients. Glandular dysfunction correlated with higher age in 
SLE and RA and an impaired health-related quality of life in 
SLE.  Conclusions: The second and third extracellular loops 
of m3AChR are antigenic in pSS. Immunoassays with anti-
gens as fusion peptides demonstrate the best performance. 
Sicca SLE patients have worse mental health status. Anti-
m3AChR antibodies represent a peculiar example of neuro-
immune interactions.  Copyright © 2012 S. Karger AG, Basel
 Introduction
 Sjögren’s syndrome (SS) is an autoimmune disease 
with multisystem involvement. It is characterized by 
chronic inflammation of the exocrine glands, particu-
larly the lachrymal and salivary glands, and a wide vari-
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 Abstract
 Objectives: Antimuscarinic acetylcholine receptor-3
(m3AChR) autoantibodies have been described in primary 
Sjögren’s syndrome (pSS). The aim of this study was to com-
pare various methods for their detection and to assess the 
contributions of anti-m3AChR and other immunological and 
psychosocial factors to the pathomechanism of secondary 
SS (sSS).  Methods: Sixty-five rheumatoid arthritis (RA) pa-
tients, 103 systemic lupus erythematosus (SLE) patients, 76 
pSS patients and 50 controls were compared. Three immu-
nodominant epitopes of m3AChR were synthesized and 
used in ELISA. Two extracellular epitopes were also prepared 
in fusion with glutathione-S-transferase and one in conjuga-
tion with bovine serum albumin. Mental health status was 
assessed with the 36-item Short-Form Health Survey and 
Functional Assessment of Chronic Illness Therapy fatigue 
scale. Correlations were evaluated between glandular func-
tion and anti-m3AChR positivities and specificities, features 
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ety of further immune-mediated organ involvement  [1] . 
In the affected secretory tissues, focal lymphocytic infil-
tration can be observed. The fundamental symptoms are 
decreased tear and saliva production, which lead to kera-
toconjunctivitis sicca and xerostomia, respectively. SS of-
ten presents as a secondary condition, when it overlaps 
with various systemic autoimmune diseases; in this case 
it is termed secondary SS (sSS), in contrast with primary 
SS (pSS) as a separate entity.
 It has previously been observed that the extent of sali-
vary gland damage caused by lymphocytic infiltration is 
not proportional to the salivary flow impairment  [2] . 
This indicates the role of other underlying mechanisms, 
such as the functional inhibition of fluid secretion. It is 
well known that the autonomic nervous system mod-
ulates saliva production through the functionally dom-
inant subtype 3 muscarinic acetylcholine receptor
(m3AChR) on acinar cells. An immune-mediated mech-
anism has been hypothesized to alter the glandular func-
tion in the target organ by means of autoantibodies which 
block the postsynaptic muscarinic receptors  [3–5] .
 Indeed, we and several other groups have demonstrat-
ed the presence of circulating autoantibodies directed 
against the m3AChR in patients with pSS  [6–12] , and 
their binding to muscarinic receptors on human salivary 
gland acinar cells has also been confirmed  [13] . Although 
several animal models and human data support the im-
portance of anti-m3AChR antibodies in pSS, these data 
mostly originate from functional assays  [14–17] , and a 
validated immunodiagnostic test is still not available. 
The exact epitope specificity of anti-m3AChR has also 
remained unidentified, which hampers their detection. 
Moreover, the prevalence and pathogenetic role of anti-
m3AChR antibodies in sSS have not been systematically 
examined.
 The pathogenesis of sSS is heterogeneous and not 
completely clear. The histological alterations in the sali-
vary glands of sSS overlapping various systemic autoim-
mune diseases are variable, as is the clinical picture  [18–
20] . Sicca symptoms are common not only in definite SS, 
but also in fibromyalgia, chronic fatigue syndrome and 
various other noninflammatory chronic diseases  [21, 22] . 
In these conditions, chronic stress and an altered neuro-
endocrine homeostasis have been hypothesized as causes 
of the exocrine insufficiency, modulated by an autonom-
ic nervous system dysfunction.
 The present study had two major objectives. First, we 
wished to determine the antigenic epitope of m3AChR 
which interacts with autoantibodies from pSS, systemic 
lupus erythematosus (SLE) and rheumatoid arthritis 
(RA) patients and also to assess the presence and clinical 
correlates of the receptor-specific autoantibodies in the 
studied disease groups. Accordingly, we attempted to de-
velop an appropriate immunodiagnostic method for the 
detection of these antibodies. As sSS is an entity with a 
complex pathogenesis, our second objective was to ad-
dress the relative contributions of immunological factors, 
and in particular anti-m3AChR antibodies, and mental 
health status to the elicitation of the sicca complex arising 
in pSS, SLE and RA.
 Patients and Methods
 Patients
 Data on 65 patients with RA and 103 with SLE were compared 
with those on 76 pSS patients and 50 healthy controls. The disease 
groups were classified according to the appropriate international 
criteria, namely the 2010 RA criteria of the American College of 
Rheumatology/European League against Rheumatism  [23] , the 
modified 1982 SLE criteria of the American College of Rheuma-
tology  [24] and the 2002 American-European Consensus Criteria 
(AECC) for SS  [25] . The mean age of the RA patients (11 male and 
54 female) was 58 years (22–82); that of the SLE patients (9 male 
and 94 female) was 48 years (25–74), and that of the pSS patients 
(2 male and 74 female) was 56 years (30–76).
 All the RA and SLE patients were systematically evaluated with 
regard to the presence of a sicca complex; following the AECC for 
SS, subjective sicca complaints were regarded as present if at least 
1 of the 3 questions included in these criteria was answered posi-
tively, while an objective exocrine deficiency was evaluated by 
means of the Schirmer test and the measurement of unstimulated 
whole saliva production. Sicca complex was established if subjec-
tive sicca symptoms of both the eye and the mouth were associated 
with at least 1 positive objective test on at least 2 separate occa-
sions. Determination of the presence of sSS as classified by the 
AECC was also attempted, but since labial salivary gland biopsy 
was not performed in several patients for ethical reasons, these as-
sessments are available for only a proportion of the patients.
 The protocol was approved by the Human Investigation Re-
view Board of the University of Szeged, Faculty of Medicine, and 
the study was performed in accordance with the principles of the 
Declaration of Helsinki. A variety of disease-specific clinical and 
immunoserological parameters of the patients were collected, and 
selected clinical and laboratory variables, including the immuno-
serological profile of SLE and RA, are presented in  table 1 .
 The impact of immunosuppressive and anticholinergic medi-
cation on the exocrine function was assessed. Therapies with 
proven anticholinergic effect were evaluated, including antihista-
minic, antidepressant, antipsychotic, antispasmodic, antiemetic 
and antiepileptic drugs. RA and SLE patients were on the usual 
immunosuppressive therapies, mostly low-dose corticosteroid, 
methotrexate, leflunomide, chloroquine, rarely sulphasalazine, 
azathioprine, cyclosporin A, cyclophosphamide, mycophenolate 
mofetil, tumor necrosis factor-  inhibitor or anti-CD20 biologic 
agents. Treatment with none of the studied medications showed a 
correlation with the presence of sicca complex (data not shown).
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 Antigen Preparation
 Three immunodominant epitopes of the human m3AChR 
were predicted by means of the computer software Peptide Com-
panion version 1.231 (Coshisoft/PeptiSearch); peptide amino ac-
ids (aa) 184–227 (AGSE) from the second extracellular loop of the 
receptor, where the ligand binding region is localized, peptide aa 
506–521 (YNIP) from the third extracellular loop and peptide aa 
360–377 (TRIC) from the third intracellular loop were selected as 
antigens.
 Multiple forms of these antigens were prepared for ELISA to 
test whether modification of m3AChR peptides could enhance 
the antigenicity and improve the detection of the autoantibodies 
specific to the respective peptides. First, short linear peptides 
were synthesized with solid-phase peptide synthesis as described 
previously  [6] . We then constructed recombinant fusion proteins 
containing the peptides AGSE and YNIP fused with glutathione-
S-transferase (GST), because it was our previous experience that 
this protein microenvironment can enhance the assumption of an 
appropriate physiological conformation  [26] . Briefly, peptide-
coding DNA sequences were assembled from synthetic oligonu-
cleotides and cloned into expression vectors in fusion with GST; 
the fusion product was expressed in  Escherichia coli and purified 
by affinity chromatography [for details, see  6 ]. Finally, the epitope 
with the highest predicted antigenicity (AGSE) was also prepared 
in multiple conjugation to bovine serum albumin (BSA) in an at-
tempt to enhance the sensitivity of the assay. We compared the 
performances of the ELISA systems by using the different forms 
of the antigens.
 ELISA Techniques
 Microtiter plates were coated with the above-mentioned anti-
gens (AGSE: 1   g/ml; YNIP and TRIC synthetic peptides: 2   g/
ml; GST fusion products and BSA-conjugated antigen: 10   g/ml). 
After incubation overnight at 4   °   C, patient sera were added at a 
dilution of 1:  200 in PBS-Tween followed by peroxidase-labeled 
antihuman IgG (1:  2,500 in PBS-Tween; Sigma-Aldrich Hungary, 
Budapest). Optical density (OD) was read at 492 and 620 nm after 
the addition of ortho-phenylenediamine to the samples. Measure-
ments were made in duplicate, and appropriate numbers of nega-
tive controls were used for every microtiter plate. For the GST- or 
BSA-conjugated proteins, the specific corrected OD characteriz-
ing the m3AChR-specific epitope within an individual sample 
was calculated by subtracting the OD for the GST or BSA protein 
from that for the GST-m3AChR peptide fusion protein or BSA-
AGSE conjugate. As the absolute OD values for the negative con-
trols varied from plate to plate, the OD values of the patients’ sam-
ples were normalized to the mean of the controls for every plate 
by dividing the OD of the test sample by the cutoff (mean + 2 SD 
of the negative control OD values). The resulting relative OD val-
ues were used for the calculations.
 Mental Health Status Assessments
 Physical and mental health were assessed with the following 
validated questionnaires: the 36-item Short-Form Health Survey 
(SF-36) and the Functional Assessment of Chronic Illness Thera-
py (FACIT) fatigue scale  [27, 28] . The SF-36 consists of 36 ques-
tions which represent multiple indicators of mental and physical 
health, including behavioral function and dysfunction, distress 
and well-being, objective reports and subjective ratings, and both 
favorable and unfavorable self-evaluations of general health status 
 [27] . The FACIT fatigue scale is a short, 13-item tool that measures 
an individual’s level of fatigue during the usual daily activities 
over the past week.
 Statistical Methods
 The differences in mean autoantibody concentrations be-
tween the studied groups were assessed with analysis of variance 
with Bonferroni’s correction as a post hoc test. The occurrences 
of positivities to the various antigenic epitopes were compared 
between the different patient and control groups with the   2  test. 
The demographic, clinical and immunoserological parameters, 
the levels of anti-m3AChR antibodies specific to the various anti-
gens and the SF-36 and FACIT results were compared between the 
RA and SLE patients with or without sicca complex through use 
of the Student t test or Fisher’s exact test, as appropriate, depend-
ing on whether continuous or categorical variables were tested. 
Levels of p  ! 0.05 were taken as statistically significant. The sta-
tistical analyses were performed with SPSS 15.0 software.
 Results
 Anti-m3AChR Detection
 The mean levels of anti-m3AChR antibodies depend-
ing on the method of antigen preparation and epitope 
specificity in the three disease groups and the healthy 
controls can be seen in  figure 1 . Significantly higher 
mean autoantibody levels to the peptide sequences cor-
responding to the second (AGSE) and third (YNIP) ex-
tracellular loops were detected in both the pSS and the 
SLE patients than in the controls, while the RA patients 
exhibited only a borderline significant difference (p = 
0.067) versus controls. This technique using short pep-
tide sequences failed to make further distinctions be-
 Table 1. C haracteristic clinical and laboratory variables of SLE
(n = 103) and RA patients (n = 65)
 SLE (n = 103)  %  RA (n = 65)  % 
 Polyarthritis  89.2  Rheumatoid nodules  12.5 
 Photosensitivity  70.6  Pulmonary fibrosis 4.7 
 Nephritis  30.4  RF  84.4 
 Serositis  28.4  Anti-MCV  77.9 
 Nervous system  21.6  Anti-SSA 9.5 
 Anti-dsDNA  74.2  Anti-SSB 7.1 
 Anti-SSA  50.5     
 Anti-SSB  38.6     
 Low C3, C4  67.6 
 A nti-dsDNA = Antibody to double-stranded DNA; anti-
SSA = anti-Sjögren’s syndrome A; anti-SSB = anti-Sjögren’s syn-
drome B; C3 = complement-3; C4 = complement-4; RF = rheuma-
toid factor; anti-MCV = antimutant citrullinated vimentin. 
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tween the pSS, SLE and RA patients. When the AGSE 
peptide was presented in fusion with GST, this form dis-
played significantly lower mean antibody levels in RA as 
compared with the other two patient groups. ELISA using 
the BSA conjugate failed to identify antibodies with suf-
ficient group-discriminative power, although the mean 
autoantibody levels to this antigen were higher in all 
three diseases than in the controls. It also became evident 
that the TRIC peptide, which is located in the intracellu-
lar portion of the m3AChR, reacted with only a small 
proportion of the sera and therefore cannot be regarded 
as antigenic in these diseases.
 An assessment of the prevalence of the studied anti-
bodies confirmed and further clarified the results ( fig. 2 ). 
Autoantibodies to the short peptide sequences of AGSE 
and YNIP occurred at significantly higher frequencies in 
all disease groups than in the controls. Furthermore, the 
use of GST fusion forms also revealed differences be-
tween the patient groups; the prevalences of GST-AGSE 
and GST-YNIP were elevated in both pSS and SLE as 
compared with RA. Furthermore, antibodies to GST-
YNIP were also able to discriminate between pSS and 
SLE patients, as these antibodies occurred at significant-
ly higher frequency in pSS than in SLE, though in SLE 
they were still significantly more prevalent than in RA or 
in the controls. In summary, short peptide sequences 
 detected anti-m3AchR with relatively high specificity but 
low sensitivity, whereas fusion with GST preserved the 
specificity and enhanced the sensitivity of detection of 
anti-GST-YNIP. Multiple peptide conjugation to BSA did 
not improve the sensitivity of the ELISA ( table 2 ).
 Clinical Correlations
 In the second part of the study, we sought clinical, im-
munological and psychosomatic correlates of the sicca 
complex arising in SLE or RA patients. Sicca symptoms 
0
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 Fig. 1. Mean relative OD values of anti-
m3AchR antibodies measured with ELI-
SA. The mean values of all studied anti-
m3AChR antibodies were significantly 
higher in both pSS and SLE patients than 
in the controls. GST-AGSE also discrimi-
nated pSS and SLE from RA.  a  p  ! 0.05 ver-
sus control;  b   p  ! 0.05 versus RA. GAG -
 SE = GST-AGSE fusion peptide; GYNIP = 
GST-YNIP fusion peptide; BAGSE = BSA-
AGSE multiple-conjugated peptide. 
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 Fig. 2. The prevalences of anti-m3AChR 
antibody positivities in the three disease 
groups and the controls. The prevalence of 
GST-YNIP showed a significant difference 
between pSS and the other groups. GST-
AGSE discriminated pSS and SLE from 
RA and the controls.  a  p  ! 0.05 versus con-
trol;  b  p  ! 0.05 versus RA;  c  p  ! 0.05 versus 
SLE. GAGSE = GST-AGSE fusion peptide; 
GYNIP = GST-YNIP fusion peptide; 
BAGSE = BSA-AGSE multiple-conjugated 
peptide. 
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were common in both SLE and RA patients; the sicca 
complex was verified in 14 RA patients (21.5%) and 27 
SLE patients (26.2%). We compared the sicca and non-
sicca patients with regard to the aspects of age, disease 
duration, disease-specific organ involvement, immuno-
serology and mental health status parameters, as well as 
antimuscarinic receptor antibody positivity and epitope 
specificity. Decreased saliva production correlated with 
increasing age in both SLE and RA. Furthermore, in the 
SLE patients with sicca complex, organic brain syndrome, 
stroke and anti-SSA antibody positivity occurred more 
frequently, whereas nephritis and lymphopenia were seen 
more rarely than in the non-sicca SLE patients, all with 
borderline significance ( table 3 ). It is noteworthy that the 
SLE patients with sicca syndrome demonstrated signifi-
cantly impaired mental health parameters on the SF-36, 
specifically on the ‘role-physical’, vitality, social function 
and mental health domains and the composite mental 
score, as compared with the non-sicca SLE patients ( ta-
ble 3 ). Conversely, the FACIT fatigue scale did not reveal 
differences between the subgroups of sicca and non-sicca 
SLE patients. In contrast, in the RA patients, no clinical 
or immunological correlates other than increasing age 
were identified that could discriminate between those 
with or without sicca complex; moreover, none of the pa-
rameters that characterize quality of life (SF-36) or fa-
tigue (FACIT) were found to correlate with the presence 
of sicca syndrome. Finally, although anti-m3AChR anti-
bodies specific to the second or third extracellular loops 
occurred in both SLE and RA patients, the prevalence 
and the mean levels of these autoantibodies were not sta-
tistically different between the patient subgroups of SLE 
or RA with or without sicca complex.
 Discussion
 This study has revealed two distinct neuroimmune in-
teractions that may contribute to the complex pathophys-
iology of pSS and sSS, namely autoantibody production 
that directly targets autonomic neurotransmitter recep-
tors, specifically m3AChR, and an altered mental health 
status that may theoretically be regarded as a central in-
hibitory mechanism of the parasympathetic innervation 
of the salivary glands.
 Anti-m3AChR autoantibodies have been hypothe-
sized to bind to the m3AChR and block the parasympa-
thetic neurotransmission  [5, 14] , thereby serving as an 
example of how a pathological immunological process 
can lead to organ dysfunction by inhibiting the normal 
function of the autonomic nervous system. Although sev-
eral experimental settings, involving rodent tissues and 
cultured human salivary glands, have supported this 
concept, formal proof of the functional role of anti-
m3AChR antibodies in humans is still lacking because 
the reliable detection of these autoantibodies has re-
mained elusive. Convincing correlations between anti-
 Table 2. S ensitivity and specificity of the tests for the detection
of anti-m3AChR antibodies to discriminate between pSS and 
healthy controls
   Sensitivity Specificity 
 AGSE  41.2% 92.0% 
 YNIP  41.2% 94.0% 
 TRIC  17.6% 92.0% 
 GAGSE  75.6% 58.1% 
 GYNIP  86.5%  100.0% 
 BAGSE  34.7% 98.2% 
 ELISA with the short synthetic peptide sequences had high 
specificity but low sensitivity in the detection of anti-m3AChR. 
Fusion with GST preserved the specificity and enhanced the sen-
sitivity of the detection of antibodies to the YNIP sequence. Mul-
tiple peptide conjugation to BSA did not improve detection. 
GAGSE = GST-AGSE fusion peptide; GYNIP = GST-YNIP fusion 
peptide; BAGSE = BSA-AGSE multiple-conjugated peptide. 
 
 
 Table 3. D ifferences in the clinical features and selected SF-36 
items of the sicca and non-sicca SLE patients
 Non-sicca
 (n = 76) 
 Sicca
 (n = 27) 
 p 
 Clinical features,  % 
 Organic brain syndrome 
1.3  11.1  0.056 
 Stroke 0 7.4  0.068 
 Anti-SSA  45.9  62.9  0.098 
 Nephritis  34.6  18.5  0.091 
 Lymphopenia  57.3  37  0.056 
 SF-36, mean values 
 Role-physical
 Vitality
 Social functioning
 Mental health
 Mental composite score 
 39.33
 46.71
 42.68
 42.12
 44.01 
    35.05
    41.70
    38.04
    36.82
    38.52 
 0.081
 0.005
 0.041
 0.048
 0.035 
 H igher SF-36 mean values represent better health status.
 Significant differences are shown in bold. Anti-SSA = anti-
Sjögren’s syndrome A. 
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muscarinic receptor antibodies in SS and other systemic 
autoimmune diseases could therefore not be addressed.
 We previously developed an ELISA assay involving the 
second extracellular loop of the human m3AChR as 
 antigen and succeeded in demonstrating anti-m3AChR 
antibodies in the majority of pSS patients  [6, 7] . Other 
investigators have also subsequently proved the presence 
of these autoantibodies, with frequencies in a rather
wide range, and even proposed further epitopes on the 
m3AChR as the targets of the immune response in pSS, 
specifically on the third extracellular loop  [10–12, 14, 28] ; 
however, others have failed to confirm our results  [17, 29, 
30] . Furthermore, the role of anti-m3AChR antibodies in 
sSS, which occurs in a large proportion of patients with 
two common systemic autoimmune diseases, SLE and 
RA, has not been examined to date.
 The results of the present study appear to confirm our 
previous findings that the second extracellular loop is an-
tigenic in pSS and that the GST fusion construct is an ap-
propriate mode of antigen presentation  [26] . In addition, 
our findings support the recent results that the third ex-
tracellular loop also contains antigenic sequences in a 
considerable proportion of pSS patients (and also in some 
SLE and RA patients). Actually, anti-GST-YNIP has 
emerged as the diagnostically most useful antibody, as it 
discriminates pSS patients from controls with the best 
balance of specificity and sensitivity, and in pSS, these 
autoantibodies occurred more frequently not only than 
in the controls or the RA patients but also than in SLE. 
Of course, this apparently better diagnostic performance 
may be independent of the putative functional signifi-
cance of the autoantibodies with various epitope speci-
ficities, and it should be noted that most of the previous 
results, including our own findings that directly visual-
ized the binding of anti-m3AChR to the receptor in hu-
man salivary glands, favored the inhibitory role of anti-
mAChR targeting the second extracellular loop, where 
the ligand-binding region is located. Therefore, we con-
clude that further validation of these results on larger pa-
tient populations and potentially more precise epitope 
mapping are needed to elucidate the exact epitope speci-
ficity and functional importance of these autoantibodies. 
Moreover, our data provide no indication as to whether 
anti-m3AChR antibodies may be related to the pathogen-
esis of sSS overlapping SLE or RA, although the examined 
patient population may well have been too small for defi-
nite conclusions to be drawn.
 Sicca symptoms often develop in chronic illnesses oth-
er than pSS. The pathogenesis of sSS overlapping differ-
ent systemic autoimmune diseases, including SLE, RA or 
scleroderma, is rather variable. An associated sSS alters 
the immunological phenotype of SLE, including the or-
gan manifestations or the immunoserologic profile  [19, 
31] . Some studies have suggested that the probability of 
the development of sicca symptoms in RA is directly cor-
related with the cumulative disease activity and the de-
gree of functional impairment, i.e. the burden of the 
chronic disease  [32] , while others did not find such asso-
ciations  [33] . A sicca syndrome clinically indistinguish-
able from SS also develops in a considerable proportion 
of patients with organ-specific autoimmune diseases, 
such as primary biliary cirrhosis, multiple sclerosis or 
gluten-sensitive enteropathy  [34] , and in other chronic 
non-immune-mediated illnesses, such as fibromyalgia or 
chronic fatigue syndrome  [35] . Another example of such 
a nonautoimmune sicca syndrome is the ‘sicca, asthenia, 
polyalgia syndrome’. It was revealed by Champey et
al.  [22] that the degree of deterioration of the quality of 
life – measured with the SF-36 as used in this study – di-
rectly correlated with the presence and severity of sicca 
symptoms in this syndrome. We therefore set out to ex-
amine whether mental health alterations, assessed with 
the SF-36 and the FACIT fatigue scale, may be associated 
with the development of a sicca syndrome in SLE or RA 
patients.
 Through the investigation of considerable numbers of 
SLE and RA patients, we have obtained new information 
about the correlates of the development of sicca syndrome 
in these diseases, mostly in SLE. Some clinical and im-
munoserological features differed between SLE patients 
with sicca syndrome and those without it, with border-
line significance. This is very similar to the findings of 
Manoussakis et al.  [19] in a larger cohort of patients and 
to the results of a recent meta-analysis  [36] and justifies 
the assessment of sicca syndrome in our SLE cohort. 
Moreover, the SLE plus sicca syndrome patients in this 
study were clearly different from those SLE patients in 
whom sicca symptoms were not present, in terms of a sig-
nificantly higher occurrence of signs of psychological 
dysfunction, specifically lower vitality, a worse percep-
tion of their mental health, difficulties in physical func-
tions reflecting the extent to which health interferes with 
usual daily activities such as work, studies or household 
duties, and worse scores on the composite index, which 
indicates a lower overall level of mental well-being as 
compared with the SLE patients without sicca symptoms. 
We have found only one publication in which health-re-
lated quality of life parameters were compared between 
SLE patients with or without sicca symptoms, and the 
findings of that study are similar to our own results in 
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that a lower perceived health-related status is correlated 
with salivary dysfunction  [37] . Our results argue in favor 
of an association between the health-related quality of life 
parameters and the evolution of sicca symptoms. These 
mental alterations may be either consequences or causes 
of the sicca symptoms, or they may have a common back-
ground. Our study design is obviously not sufficient to 
allow an exploration of causal relationships, but some 
data do suggest that chronic stress has a direct impact on 
saliva production and may lead to chronic xerostomia 
 [38, 39] . Salivary levels of cortisol and chromogranin A 
have been found to be increased in subjects with low sal-
ivary flow rates  [40] . Profound alterations in neurotrans-
mitter homeostasis in SS were long ago observed by San-
tavirta et al.  [41] ; both the vasoactive intestinal peptide 
and the neuropeptide Y contents (markers of parasympa-
thetic and sympathetic nervous system activity, respec-
tively) in the saliva were found to differ from those in 
healthy subjects. As indicated by the results of a number 
of other investigations  [42, 43] , it is reasonable to hypoth-
esize that chronic stress, depression and several further 
features of the long-standing distress associated with a 
systemic autoimmune illness such as SLE  [44] may nega-
tively influence the salivary gland function and are fac-
tors that should be addressed during the care of these 
patients.
 One limitation of our study is that many of the SLE 
and RA patients with sicca syndrome did not strictly 
meet the criteria of sSS. This is mostly explained by the 
fact that very few patients underwent labial salivary gland 
biopsy once the diagnosis of SLE and RA had been veri-
fied, mostly because of patient refusal, anticoagulant 
therapy or the lack of specific therapeutic consequences. 
However, it should be emphasized that all the sicca syn-
drome patients consequently gave positive answers to the 
sicca questionnaire on at least two separate occasions and 
had markedly and repeatedly low salivary and lachrymal 
flow rates. The variability of these test results was low 
(data not shown), and these patients could prudently be 
regarded as patients with sSS in clinical practice.
 In summary, the results of the present study indicate 
that a probably polyclonal autoimmune reaction to mul-
tiple epitopes on the m3AChR is observed most promi-
nently in pSS, but also in SLE and RA, and the fusion of 
these antigenic peptides to GST may – after further vali-
dation – be a promising laboratory test for further re-
search and possibly for the diagnosis of pSS. Further-
more, an impaired level of psychosocial well-being and a 
dysfunctional stress response may be contributors to the 
pathogenesis of sSS in SLE.
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